Bradycardia is having a heart rate of <60 beats/minute that may not affect the hemodynamic status of some patients.
A heart rate that is
inadequate for the patient's current condition and may not be able to
support life is a clinically significant bradycardia.
Bradycardia can be caused by problems in the sinoatrial node, problems in the conduction pathways of the heart, metabolic problems or heart attack/disease that caused damage to the heart.
The different types of bradycardia are sinus bradycardia, sick sinus syndrome, tachycardia-bradycardia syndrome, hypersensitive carotid sinus syndrome, sinus pause/arrest, sinoatrial node exit block and atrioventricular block.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.